Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil - The Lancet
How swamped preprint servers are blocking bad coronavirus research
Elsevier: Preprints With The Lancet Launches on SSRN
Reporting and data sharing level for COVID-19 vaccine trials: A cross-sectional study - eBioMedicine
Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: a multinational, observational study - The Lancet
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial - The Lancet
Retracted coronavirus (COVID-19) papers – Retraction Watch
Collaborative Research: Community Health Impact Coalition Lancet Preprint - Research - Community Health Toolkit
Preprints and Preprint Server Update - Science Editor
Congrats to Dr. Therriault and team on their amazing preprint in The Lancet! 👏 🧠 | ALZpath Inc. posted on the topic | LinkedIn
Early in the epidemic: impact of preprints on global discourse about COVID-19 transmissibility - The Lancet Global Health
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial - The Lancet Infectious Diseases
Flawed preprint based on autopsies inadequate to demonstrate that COVID-19 vaccines caused 74% of those deaths - Health Feedback
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial - The Lancet Infectious Diseases
Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study - The Lancet
eBioMedicine Home Page
Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic - The Lancet
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study - The Lancet
The Lancet Commission on lessons for the future from the COVID-19 pandemic - The Lancet
An interactive website tracking COVID-19 vaccine development - The Lancet Global Health
Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis - The Lancet Global Health
Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression - The Lancet Infectious Diseases
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial - The Lancet Infectious Diseases
Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study - The Lancet Infectious Diseases
Robustness of evidence reported in preprints during peer review - The Lancet Global Health
